Design and Development of a Chemical Probe for Pseudokinase Ca2+/calmodulin-Dependent Ser/Thr Kinase.

CASK (Ca2+/calmodulin-dependent Ser/Thr kinase) is a member of the MAGUK (membrane-associated guanylate kinase) family that functions as neurexin kinases with roles implicated in neuronal synapses and trafficking. The lack of a canonical DFG motif, which is altered to GFG in CASK, led to the classification as a pseudokinase. However, functional studies revealed that CASK can still phosphorylate substrates in the absence of divalent metals. CASK dysfunction has been linked to many diseases, including colorectal cancer, Parkinson's disease, and X-linked mental retardation, suggesting CASK as a potential drug target. Here, we exploited structure-based design for the development of highly potent and selective CASK inhibitors based on 2,4-diaminopyrimidine-5-carboxamides targeting an unusual pocket created by the GFG motif. The presented inhibitor design offers a more general strategy for the development of pseudokinase ligands that harbor unusual sequence motifs. It also provides a first chemical probe for studying the biological roles of CASK.

[1]  D. Fabbro,et al.  Trends in kinase drug discovery: targets, indications and inhibitor design , 2021, Nature Reviews Drug Discovery.

[2]  P. Jänne,et al.  Kinase drug discovery 20 years after imatinib: progress and future directions , 2021, Nature Reviews Drug Discovery.

[3]  M. Galsky,et al.  A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations , 2021, Investigational New Drugs.

[4]  Yuan Li,et al.  CASK regulates Notch pathway and functions as a tumor promoter in pancreatic cancer. , 2021, Archives of biochemistry and biophysics.

[5]  A. Schlessinger,et al.  Type II Binders Targeting the "GLR-Out" Conformation of the Pseudokinase STRADα. , 2021, Biochemistry.

[6]  S. Cook,et al.  Inhibition of RAF dimers: it takes two to tango , 2020, Biochemical Society transactions.

[7]  N. Gray,et al.  Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development , 2020, Cell.

[8]  D. James,et al.  CASK modulates the assembly and function of the Mint1/Munc18-1 complex to regulate insulin secretion , 2020, Cell Discovery.

[9]  Hyung‐Ok Kim.  Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors , 2020, Archives of Pharmacal Research.

[10]  Samara L. Reck-Peterson,et al.  Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction , 2020, Nature.

[11]  Fiona Pachl,et al.  Discovery of PROTAC molecules that selectively degrade the IRAK3 pseudokinase. , 2020, Journal of medicinal chemistry.

[12]  S. Knapp,et al.  Nucleotide Binding, Evolutionary Insights, and Interaction Partners of the Pseudokinase Unc-51-like Kinase 4. , 2020, Structure.

[13]  S. Knapp,et al.  Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. , 2020, Molecules and Cells.

[14]  M B Robers,et al.  Quantifying Target Occupancy of Small Molecules Within Living Cells. , 2020, Annual review of biochemistry.

[15]  J. Smaill,et al.  New Promise and Opportunities for Allosteric Kinase Inhibitors. , 2019, Angewandte Chemie.

[16]  T. Willson,et al.  The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification , 2019, bioRxiv.

[17]  S. Bölte,et al.  Presynaptic dysfunction in CASK-related neurodevelopmental disorders , 2019, bioRxiv.

[18]  K. Keeshan,et al.  Pseudokinases: a tribble‐edged sword , 2019, The FEBS journal.

[19]  S. Spergel,et al.  Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. , 2019, Journal of medicinal chemistry.

[20]  S. Spergel,et al.  CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH Compound_5 AKA 4-[(2-CARBAMOYLPHEN YL)AMINO]-6-[(5-FLUOROPYRIDIN-2-YL)AMINO]-N-METHYLPYRIDINE -3-CARBOXAMIDE , 2019 .

[21]  N. Jura,et al.  Prospects for pharmacological targeting of pseudokinases , 2019, Nature Reviews Drug Discovery.

[22]  M. Nouri,et al.  Cover Image, Volume 120, Number 1, January 2019 , 2018, Journal of Cellular Biochemistry.

[23]  Harlan R. Barker,et al.  Targeting Wnt signaling pseudokinases in hematological cancers , 2018, European journal of haematology.

[24]  K. Devriendt,et al.  Novel CASK mutations in cases with syndromic microcephaly , 2018, Human mutation.

[25]  T. Willson,et al.  Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement , 2017, Cell chemical biology.

[26]  Xiaodong Wang,et al.  Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein. , 2017, Chemical communications.

[27]  Stephen J. Capuzzi,et al.  Progress towards a public chemogenomic set for protein kinases and a call for contributions , 2017, bioRxiv.

[28]  S. Knapp,et al.  The ins and outs of selective kinase inhibitor development. , 2015, Nature chemical biology.

[29]  P. Jänne,et al.  Development of small molecules targeting the pseudokinase Her3. , 2015, Bioorganic & medicinal chemistry letters.

[30]  S. Hubbard,et al.  Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. , 2015, Blood.

[31]  P. Jänne,et al.  Pharmacological Targeting of the Pseudokinase Her3 , 2014, Nature chemical biology.

[32]  Min Fang,et al.  High expression of CASK correlates with progression and poor prognosis of colorectal cancer , 2014, Tumor Biology.

[33]  A. Kurosaka,et al.  A rapid and efficient method for neuronal induction of the P19 embryonic carcinoma cell line , 2014, Journal of Neuroscience Methods.

[34]  N. Powell,et al.  Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. , 2013, Bioorganic & medicinal chemistry letters.

[35]  T. Südhof,et al.  Evolution of CASK into a Mg2+-Sensitive Kinase , 2010, Science Signaling.

[36]  Stefan Knapp,et al.  Structure of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding Site , 2009, Structure.

[37]  A. Määttä,et al.  The MAGUK-family protein CASK is targeted to nuclei of the basal epidermis and controls keratinocyte proliferation , 2008, Journal of Cell Science.

[38]  T. Südhof,et al.  CASK Functions as a Mg2+-Independent Neurexin Kinase , 2008, Cell.

[39]  G. Barton,et al.  Emerging roles of pseudokinases. , 2006, Trends in cell biology.

[40]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[41]  Zhihua Liu,et al.  CASK and its target gene Reelin were co-upregulated in human esophageal carcinoma. , 2002, Cancer letters.

[42]  I. Lucet,et al.  Characterization of Ligand Binding to Pseudokinases Using a Thermal Shift Assay. , 2017, Methods in molecular biology.

[43]  Stefan Knapp,et al.  Kinase inhibitor selectivity profiling using differential scanning fluorimetry. , 2012, Methods in molecular biology.